Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 6—June 2005

Research

Emergence and Spread of Streptococcus pneumoniae with erm(B) and mef(A) Resistance

David J. Farrell*Comments to Author , Stephen G. Jenkins†, Steven D. Brown‡, Manish Patel§, Bruce S. Lavin§, and Keith P. Klugman¶#
Author affiliations: *G.R. Micro Ltd, London, United Kingdom; †Mount Sinai School of Medicine, New York, New York, USA; ‡Clinical Microbiology Institute, Wilsonville, Oregon, USA; §sanofi-aventis, Bridgewater, New Jersey, USA; ¶Emory University, Atlanta, Georgia, USA; #University of the Witwatersrand, Johannesburg, South Africa

Main Article

Table 4

Susceptibility to various antibacterial drugs among Streptococcus pneumoniae isolates collected from years 1–3 of the PROTEKT US study that had both erm(B) and mef(A) macrolide resistance genes (n = 1,159)

Drug % susceptibility*
Susceptible Intermediate Resistant
Amoxicillin–clavulanate† 40.6 22.0 37.4
Azithromycin 0 0.1 99.9
Cefuroxime 5.7 1.7 92.6
Clarithromycin 0 0 100
Co-trimoxazole 3.4 1.2 95.4
Erythromycin 0 0 100
Levofloxacin 98.6 0 1.4
Linezolid 99.8 0 0.2
Penicillin 1.5 6.7 91.8
Telithromycin 99.0 0.9 0.1
Tetracycline 2.7 0.7 96.6

*Susceptibility was defined according to Clinical and Laboratory Standards Institute interpretive criteria (25).
†Amoxicillin alone was not tested; however, susceptibility can be extrapolated from the amoxicillin-clavulanate results.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO